Announcement on Convening the Q1 2026 Performance Briefing
Filed with SSE · · 3 pages · Chinese
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 3rd Lifting Period of Initially Granted Part under Restricted Stock Incentive Plan of 2021
- Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. for Mannitol Injection
- Announcement on Changing Registered Capital and Amending the Articles of Association
- Announcement on Obtaining Drug Registration Certificate for Sodium Valproate Oral Solution by Holding Subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
- Announcement on Convening the 2025 Annual Performance Briefing
Later from China Resources Double-Crane Pharmaceutical
- Announcement on ObtainingApproval Notice for the Supplementary Application of Drug for Dienogest Tablets by Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd.
- Announcement on Acquiring 100% Equity of Nanjing Xinbai Pharmaceutical Co., Ltd. and Related Party Transactions
- Announcement on Completion of Phase III Drug Clinical Trial
- Announcement on Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium, Potassium, Magnesium and Calcium Concentrated Solution for Injection
- Announcement on Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Ezetimibe Tablets
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical